CXCL2 is an ELR CXC chemokine that is structurally and functionally related to GRO1 (CXCL1), GRO3 (CXCL3), and interleukin-8 (CXCL8). CXCL2 binds to the CXCR2 receptor, which is shared with other ELR CXC chemokines, including CXCL1, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8. CXCL2 is highly expressed in esophageal squamous cell carcinoma (ESCC), and has been detected in the serum of patients with this disease. Elevated levels of CXCL1, CXCL2 and CXCL3 have also been observed in patients with malignant melanoma.In addition, CXCL2 and CXCL1 are upregulated in the central nervous system in multiple sclerosis (MS) and in the animal model of experimental autoimmune encephalomyelitis (EAE). In EAE, the transfer of encephalitogenic CD4+Th17 cells induces CXCL1 and CXCL2 transcription in the spinal cords of naïve, syngeneic recipients. IL-17 is a potent inducer of ELR+CXC chemokines in both MS and EAE, with CXCL1 and CXCL2 shown to be upregulated in the preclinical and clinical stages of EAE. Additionally, CXCL1 and CXCL2 are secreted by epithelial cells in the bone marrow, while CXCL2 is secreted by endothelial cells during G-CSF-induced neutrophil mobilization.

PRODUCT DETAILS

Clone: A21113C

Antibody Type: Monoclonal

Reactivity: Mouse

Format: CXCL2

Host: Rat

Isotype: IgG2b, κ

Applications: ICFC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.